Skip to main content
SpringerLink
Log in

Patient-Reported Outcomes in Lung Cancer

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 322 Accesses

Abstract

Despite painstaking efforts to optimize the multimodality treatment for lung cancer patients, lung cancer remains a leading cause of all cancer deaths worldwide. The quality of life (QoL) for these patients, therefore, is of utmost importance. Quality of life, a key patient-reported outcome (PRO), has garnered great interest over the last few decades and has become a key clinically meaningful endpoint in developing cancer clinical trials, especially for lung cancer. This chapter provides a review of the clinical relevance, measurement, analysis, and challenges faced when assessing PROs in lung cancer trials. Key examples of pertinent quality-of-life studies related to lung cancer and, particularly radiation therapy, are also included.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365

    Article  Google Scholar 

  • Anonymous (1993) Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual Life Res 2(2):153–159

    Article  Google Scholar 

  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y-C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929. https://doi.org/10.1056/NEJMoa1709937

    Article  Google Scholar 

  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y-C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697

    Article  Google Scholar 

  • Basch E (2019) High compliance rates with patient-reported outcomes in oncology trials submitted to the US Food and Drug Administration. J Natl Cancer Inst 111(5):437–439. https://doi.org/10.1093/jnci/djy183

    Article  Google Scholar 

  • Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D (2007) Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc 14(3):264–268. https://doi.org/10.1197/jamia.M2177

    Article  Google Scholar 

  • Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632. https://doi.org/10.1093/jnci/djp386

    Article  Google Scholar 

  • Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565. https://doi.org/10.1200/JCO.2015.63.0830

    Article  Google Scholar 

  • Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318(2):197–198. https://doi.org/10.1001/jama.2017.7156

    Article  Google Scholar 

  • Beacon HJ, Thompson SG (1996) Multi-level models for repeated measurement data: application to quality of life data in clinical trials. Stat Med 15(24):2717–2732. https://doi.org/10.1002/(SICI)1097-0258(19961230)15:24<2717::AID-SIM518>3.0.CO;2-E

    Article  Google Scholar 

  • Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A(5):635–642. https://doi.org/10.1016/0959-8049(94)90535-5

    Article  Google Scholar 

  • Berman AT, Rosenthal SA, Moghanaki D, Woodhouse KD, Movsas B, Vapiwala N (2016) Focusing on the “person” in personalized medicine: the future of patient-centered care in radiation oncology. J Am Coll Radiol 13(12 Pt B):1571–1578. https://doi.org/10.1016/j.jacr.2016.09.012

    Article  Google Scholar 

  • Bonnetain F, Fiteni F, Efficace F, Anota A (2016) Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. J Clin Oncol 34(16):1953–1956. https://doi.org/10.1200/JCO.2014.56.7974

    Article  Google Scholar 

  • Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH (2003) Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol 21(15):2982–2992. https://doi.org/10.1200/JCO.2003.01.203

    Article  Google Scholar 

  • Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199. https://doi.org/10.1016/S1470-2045(14)71207-0

    Article  Google Scholar 

  • Braun DP, Gupta D, Staren ED (2011) Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer 11:353. https://doi.org/10.1186/1471-2407-11-353

    Article  Google Scholar 

  • Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413. https://doi.org/10.1200/JCO.1997.15.6.2403

    Article  Google Scholar 

  • Butt Z, Webster K, Eisenstein AR, Beaumont J, Eton D, Masters GA, Cella D (2005) Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale. Hematol Oncol Clin North Am 19(2):389–420, viii. https://doi.org/10.1016/j.hoc.2005.02.009

    Article  Google Scholar 

  • Calvert M, Brundage M, Jacobsen PB, Schünemann HJ, Efficace F (2013) The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice. Health Qual Life Outcomes 11:184. https://doi.org/10.1186/1477-7525-11-184

    Article  Google Scholar 

  • Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT, the SPIRIT-PRO Group, Hunn A, Bottomley A, Regnault A, Chan A-W, Ells C, O’Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T (2018) Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA 319(5):483–494. https://doi.org/10.1001/jama.2017.21903

    Article  Google Scholar 

  • Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579. https://doi.org/10.1200/JCO.1993.11.3.570

    Article  Google Scholar 

  • Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12(3):199–220. https://doi.org/10.1016/0169-5002(95)00450-f

    Article  Google Scholar 

  • Center for Drug Evaluation and Research (2020) Patient-reported outcome measures: use in medical product development to support labeling claims. US Food Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed 1 Sep 2020

  • Claassens L, van Meerbeeck J, Coens C, Quinten C, Ghislain I, Sloan EK, Wang XS, Velikova G, Bottomley A (2011) Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 29(15):2104–2120. https://doi.org/10.1200/JCO.2010.32.3683

    Article  Google Scholar 

  • Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner H-H, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, O’Connor D, Oliver K, Piault-Louis E, Piccart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A, Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (2020) International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol 21(2):e83–e96. https://doi.org/10.1016/S1470-2045(19)30790-9

    Article  Google Scholar 

  • Damm K, Roeske N, Jacob C (2013) Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev 3(1):15. https://doi.org/10.1186/2191-1991-3-15

    Article  Google Scholar 

  • Denis F, Viger L, Charron A, Voog E, Dupuis O, Pointreau Y, Letellier C (2014) Detection of lung cancer relapse using self-reported symptoms transmitted via an internet web-application: pilot study of the sentinel follow-up. Support Care Cancer 22(6):1467–1473. https://doi.org/10.1007/s00520-013-2111-1

    Article  Google Scholar 

  • Denis F, Basch E, Septans A-L, Bennouna J, Urban T, Dueck AC, Letellier C (2019) Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA 321(3):306–307. https://doi.org/10.1001/jama.2018.18085

    Article  Google Scholar 

  • Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O’Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E, National Cancer Institute PRO-CTCAE Study Group (2015) Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059. https://doi.org/10.1001/jamaoncol.2015.2639

    Article  Google Scholar 

  • Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953. https://doi.org/10.1002/ijc.31937

    Article  Google Scholar 

  • Fernández-López C, Expósito-Hernández J, Arrebola-Moreno JP, Calleja-Hernández MÁ, Expósito-Ruíz M, Guerrero-Tejada R, Linares I, Cabeza-Barrera J (2016) Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer. Cancer Med 5(9):2190–2197. https://doi.org/10.1002/cam4.782

    Article  Google Scholar 

  • Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V (2016) Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. Eur J Cancer 52:120–128. https://doi.org/10.1016/j.ejca.2015.10.004

    Article  Google Scholar 

  • Ganz PA, Lee JJ, Siau J (1991) Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer 67(12):3131–3135. https://doi.org/10.1002/1097-0142(19910615)67:12<3131::aid-cncr2820671232>3.0.co;2-4

    Article  Google Scholar 

  • Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai J-S, Reeve BB, Smith AW, Stone AA, Weinfurt K (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25(32):5106–5112. https://doi.org/10.1200/JCO.2007.12.2341

    Article  Google Scholar 

  • Gelber RD, Gelber S (1995) Quality-of-life assessment in clinical trials. Cancer Treat Res 75:225–246. https://doi.org/10.1007/978-1-4615-2009-2_11

    Article  Google Scholar 

  • Gotay CC (2004) Assessing cancer-related quality of life across a spectrum of applications. J Natl Cancer Inst Monogr (33):126–133. https://doi.org/10.1093/jncimonographs/lgh004

  • Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ (2019) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol 20(12):1670–1680. https://doi.org/10.1016/S1470-2045(19)30519-4

    Article  Google Scholar 

  • Husted JA, Cook RJ, Farewell VT, Gladman DD (2000) Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 53(5):459–468. https://doi.org/10.1016/s0895-4356(99)00206-1

    Article  Google Scholar 

  • Johnson JR, Temple R (1985) Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69(10):1155–1159

    Google Scholar 

  • Kaasa S, Mastekaasa A, Lund E (1989) Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients’ subjective experience of disease and psychosocial well-being. Radiother Oncol 15(3):235–242. https://doi.org/10.1016/0167-8140(89)90091-1

    Article  Google Scholar 

  • Kluetz PG, O’Connor DJ, Soltys K (2018) Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol 19(5):e267–e274. https://doi.org/10.1016/S1470-2045(18)30097-4

    Article  Google Scholar 

  • Langendijk H, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Wouters M (2000) The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55(1):19–25. https://doi.org/10.1016/s0167-8140(00)00158-4

    Article  Google Scholar 

  • Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73(10):2535–2542. https://doi.org/10.1002/1097-0142(19940515)73:10<2535::aid-cncr2820731014>3.0.co;2-5

    Article  Google Scholar 

  • Leplège A (1997) The problem of quality of life in medicine. JAMA 278(1):47. https://doi.org/10.1001/jama.1997.03550010061041

    Article  Google Scholar 

  • Lizée T, Basch E, Trémolières P, Voog E, Domont J, Peyraga G, Urban T, Bennouna J, Septans A-L, Balavoine M, Detournay B, Denis F (2019) Cost-effectiveness of web-based patient-reported outcome surveillance in patients with lung cancer. J Thorac Oncol 14(6):1012–1020. https://doi.org/10.1016/j.jtho.2019.02.005

    Article  Google Scholar 

  • Low CA (2020) Harnessing consumer smartphone and wearable sensors for clinical cancer research. NPJ Digit Med 3(1):1–7. https://doi.org/10.1038/s41746-020-00351-x

    Article  Google Scholar 

  • Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati SF, Bertetto O, Novello S, Migliorino MR, Favaretto A, Spatafora M, Ferraù F, Frontini L, Bearz A, Repetto L, Gridelli C, Barletta E, Barzelloni ML, Iaffaioli RV, De Maio E, Di Maio M, De Feo G, Sigoriello G, Chiodini P, Cioffi A, Guardasole V, Angelini V, Rossi A, Bilancia D, Germano D, Lamberti A, Pontillo V, Brancaccio L, Renda F, Romano F, Esani G, Gambaro A, Vinante O, Azzarello G, Clerici M, Bollina R, Belloni P, Sannicolò M, Ciuffreda L, Parello G, Cabiddu M, Sacco C, Sibau A, Porcile G, Castiglione F, Ostellino O, Monfardini S, Stefani M, Scagliotti G, Selvaggi G, De Marinis F, Martelli O, Gasparini G, Morabito A, Gattuso D, Colucci G, Galetta D, Giotta F, Gebbia V, Borsellino N, Testa A, Malaponte E, Capuano MA, Angiolillo M, Sollitto F, Tirelli U, Spazzapan S, Adamo V, Altavilla G, Scimone A, Hopps MR, Tartamella F, Ianniello GP, Tinessa V, Failla G, Bordonaro R, Gebbia N, Valerio MR, D’Aprile M, Veltri E, Tonato M, Darwish S, Romito S, Carrozza F, Barni S, Ardizzoia A, Corradini GM, Pavia G, Belli M, Colantuoni G, Galligioni E, Caffo O, Labianca R, Quadri A, Cortesi E, D’Auria G, Fava S, Calcagno A, Luporini G, Locatelli MC, Di Costanzo F, Gasperoni S, Isa L, Candido P, Gaion F, Palazzolo G, Nettis G, Annamaria A, Rinaldi M, Lopez M, Felletti R, Di Negro GB, Rossi N, Calandriello A, Maiorino L, Mattioli R, Celano A, Schiavon S, Illiano A, Raucci CA, Caruso M, Foa P, Tonini G, Curcio C, Cazzaniga M (2005) Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23(28):6865–6872. https://doi.org/10.1200/JCO.2005.02.527

    Article  Google Scholar 

  • Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Crowley J (1989) Quality of life end points in cancer clinical trials: review and recommendations. J Natl Cancer Inst 81(7):485–495. https://doi.org/10.1093/jnci/81.7.485

    Article  Google Scholar 

  • Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31(2–3):233–240. https://doi.org/10.1016/s0169-5002(00)00179-3

    Article  Google Scholar 

  • Movsas B (2015) Proceeding with the patient-reported outcomes (PROs) version of the common terminology criteria for adverse events. JAMA Oncol 1(8):1059–1060. https://doi.org/10.1001/jamaoncol.2015.2689

    Article  Google Scholar 

  • Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23(10):2145–2154. https://doi.org/10.1200/JCO.2005.07.167

    Article  Google Scholar 

  • Movsas B, Moughan J, Sarna L, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Wasserman T, Bruner DW (2009) Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 27(34):5816–5822. https://doi.org/10.1200/JCO.2009.23.7420

    Article  Google Scholar 

  • Movsas B, Hunt D, Watkins-Bruner D, Lee WR, Tharpe H, Goldstein D, Moore J, Dayes IS, Parise S, Sandler H (2014) Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. Pract Radiat Oncol 4(3):187–191. https://doi.org/10.1016/j.prro.2013.07.014

    Article  Google Scholar 

  • Movsas B, Hu C, Sloan J, Bradley J, Komaki R, Masters G, Kavadi V, Narayan S, Michalski J, Johnson DW, Koprowski C, Curran WJ, Garces YI, Gaur R, Wynn RB, Schallenkamp J, Gelblum DY, MacRae RM, Paulus R, Choy H (2016) Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial. JAMA Oncol 2(3):359–367. https://doi.org/10.1001/jamaoncol.2015.3969

    Article  Google Scholar 

  • Nicklasson M, Bergman B (2007) Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting. Qual Life Res 16(6):1019–1028. https://doi.org/10.1007/s11136-007-9210-8

    Article  Google Scholar 

  • Nunnaly J, Bernstein I (1994) Psychometric therapy. McGraw-Hill, New York

    Google Scholar 

  • Office of the Commissioner (2019) Food and Drug Administration Safety and Innovation Act (FDASIA). FDA. https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-administration-safety-and-innovation-act-fdasia. Accessed 12 Dec 2020

  • Ohri N, Halmos B, Bodner WR, Cheng H, Guha C, Kalnicki S, Garg M (2019) Daily step counts: a new prognostic factor in locally advanced non-small cell lung cancer? Int J Radiat Oncol Biol Phys 105(4):745–751. https://doi.org/10.1016/j.ijrobp.2019.07.055

    Article  Google Scholar 

  • Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J (1996) Quality of life studies in chemotherapy-induced emesis. Oncology 53(Suppl 1):92–95. https://doi.org/10.1159/000227647

    Article  Google Scholar 

  • Qi Y, Schild SE, Mandrekar SJ, Tan AD, Krook JE, Rowland KM, Garces YI, Soori GS, Adjei AA, Sloan JA (2009) Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol 4(9):1075–1082. https://doi.org/10.1097/JTO.0b013e3181ae27f5

    Article  Google Scholar 

  • Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, Osoba D, Bjordal K, Bottomley A, EORTC Clinical Groups (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10(9):865–871. https://doi.org/10.1016/S1470-2045(09)70200-1

    Article  Google Scholar 

  • Reale ML, De Luca E, Lombardi P, Marandino L, Zichi C, Pignataro D, Ghisoni E, Di Stefano RF, Mariniello A, Trevisi E, Leone G, Muratori L, La Salvia A, Sonetto C, Bironzo P, Aglietta M, Novello S, Scagliotti GV, Perrone F, Di Maio M (2020) Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018. Lung Cancer 139:47–54. https://doi.org/10.1016/j.lungcan.2019.10.022

    Article  Google Scholar 

  • Rubin D (2004) Multiple imputation for nonresponse in surveys. Wiley, Hoboken, NJ

    MATH  Google Scholar 

  • Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Byhardt R, Wasserman T, Movsas B (2008) Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 72(5):1378–1384. https://doi.org/10.1016/j.ijrobp.2008.03.003

    Article  Google Scholar 

  • Siddiqui F, Liu AK, Watkins-Bruner D, Movsas B (2014) Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. J Clin Oncol 32(26):2920–2927. https://doi.org/10.1200/JCO.2014.55.0707

    Article  Google Scholar 

  • Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57(1):109–112. https://doi.org/10.1038/bjc.1988.20

    Article  Google Scholar 

  • Sprangers MAG, Thong MSY, Bartels M, Barsevick A, Ordoñana J, Shi Q, Wang XS, Klepstad P, Wierenga EA, Singh JA, Sloan JA, GeneQol Consortium (2014) Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Qual Life Res 23(7):1997–2013. https://doi.org/10.1007/s11136-014-0656-1

    Article  Google Scholar 

  • Testa MA, Simonson DC (1996) Assessment of quality-of-life outcomes. N Engl J Med 334(13):835–840. https://doi.org/10.1056/NEJM199603283341306

    Article  Google Scholar 

  • US Food and Drug Administration (2013) The voice of the patient. A series of reports from the U.S. Food and Drug Administration’s (FDA’s) patient-focused drug development initiative. Lung Cancer. https://www.fda.gov/downloads/drugs/newsevents/ucm464932.pdf. Accessed 3 Feb 2021

  • US Food and Drug Administration (2020) Patient-focused drug development program. https://www.fda.gov/about-fda/oncology-center-excellence/patient-focused-drug-development. Accessed 3 Feb 2021

  • van der Weijst L, Surmont V, Schrauwen W, Lievens Y (2017) Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: has it yet become state-of-the-art? Crit Rev Oncol Hematol 119:40–49. https://doi.org/10.1016/j.critrevonc.2017.09.014

    Article  Google Scholar 

  • Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, Cella D (1995) RTOG’s first quality of life study—RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33(4):901–906. https://doi.org/10.1016/0360-3016(95)02002-5

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin-Madison School of Public Health and Medicine, Madison, WI, USA

    Newton J. Hurst Jr

  2. Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, MI, USA

    Farzan Siddiqui & Benjamin Movsas

Authors
  1. Newton J. Hurst Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farzan Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin Movsas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Movsas .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hurst, N.J., Siddiqui, F., Movsas, B. (2022). Patient-Reported Outcomes in Lung Cancer. In: Jeremić, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2022_338

Download citation

  • DOI: https://doi.org/10.1007/174_2022_338

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-34846-4

  • Online ISBN: 978-3-031-34847-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation